Accessibility Menu
Revive Therapeutics logo

Revive Therapeutics(OTC) RVVTF

Current Price$0.02
Market Cap$7.53MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2015)-97%
5 Year-96%
1 Year+36%
1 Month-2%
Revive Therapeutics last closing stock price
MetricPriceDate
Last closeUSD 0.022026-07-24
Revive Therapeutics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-21.74%USD 0.022026-07-17
1 month-2.17%USD 0.022026-06-24
3 month-39.19%USD 0.032026-04-24
Year to date+118.18%USD 0.012025-12-31
1 year+35.85%USD 0.012025-07-24
3 year-33.33%USD 0.032023-07-25
5 year-95.84%USD 0.432021-07-23
Since inception-96.57%USD 0.522015-12-02

Revive Therapeutics Financials at a Glance

Market Cap

$7.53MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

CA$0.00

Net Income (TTM)

-CA$10.63M

EPS (TTM)

-$0.02

P/E Ratio

-0.99

Dividend

$0.00

Beta (Volatility)

0.01 (Low)

Price

$0.02

Volume

17,993

Open

$0.02

Previous Close

$0.02

Daily Range

$0.02 - $0.02

52-Week Range

$0.00 - $0.06

Estimated Earnings Date

May 27, 2026

RVVTF News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Revive Therapeutics

Revive Therapeutics Ltd. is a life sciences company based in Toronto, Canada, dedicated to developing innovative treatments for rare diseases and infectious illnesses. Founded in 2012, the company focuses on a pharmaceutical pipeline that emphasizes cannabinoids and psychedelic compounds.

Products and Services
  • Bucillamine: In Phase 3 trials for infectious diseases like influenza and COVID-19
  • Psilocybin: Undergoing Phase 1 studies for methamphetamine use disorder
  • Cannabidiol (CBD): Investigating applications for autoimmune hepatitis and organ transplant injuries
Growth Outlook
  • Strategic partnerships with PharmaTher and universities enhance research capabilities
  • Ongoing clinical trials may lead to significant market opportunities
  • Focus on rare inflammatory conditions positions the company in a niche market
Financial Highlights
  • Recent quarterly net income of -$507,813 reflects ongoing investment in R&D
  • Trailing twelve months (TTM) revenue remains at $0, indicating early-stage development
  • Market capitalization of approximately $9.58 million suggests potential for growth
Revive Therapeutics Ltd. is actively engaged in advancing its therapeutic portfolio, which includes promising compounds like Bucillamine and psilocybin. The company’s strategic collaborations with academic institutions and other firms aim to enhance its research capabilities and expedite the development of its products. Despite facing financial challenges, including a recent quarterly net loss, the focus on rare diseases and innovative treatments positions Revive Therapeutics as a potentially valuable player in the healthcare sector. The company's market capitalization indicates room for growth, especially as clinical trials progress and partnerships expand.
AI Generated • Jul 21, 2026

Industry

Pharmaceuticals

Sector

Health Care

CEO

Michael Frank

Website

www.revivethera.com

Headquarters

Toronto, ON M5C 1P1, CA

RVVTF Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

288.66%

Return on Capital

N/A

Return on Assets

-3770.35%

Earnings Yield

-1.01%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$7.53MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

418.56M

Volume

17.99K

Avg. Volume

208.77K

Financials (TTM)

Gross Profit

-CA$95.08

Operating Income

-CA$1.30M

EBITDA

-CA$10.62M

Operating Cash Flow

-CA$156.71K

Capital Expenditure

CA$0.00

Free Cash Flow

-CA$156.71K

Cash & ST Invst.

CA$22.72K

Total Debt

CA$70.95K

Revive Therapeutics Performance Analysis

Revive Therapeutics annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-06-30CAD 0N/A
20232023-06-30CAD 0N/A
20242024-06-30CAD 0N/A
20252025-06-30CAD 0N/A
Revive Therapeutics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42025-06-30N/A
Q12025-09-30N/A
Q22025-12-31N/A
Q32026-03-31N/A
Revive Therapeutics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-06-30CAD -0.04N/A
20232023-06-30CAD -0.01-68.4%
20242024-06-30CAD -0.01-21.6%
20252025-06-30CAD -0.0272.5%
Revive Therapeutics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42025-06-30-1514.3%
Q12025-09-3096.9%
Q22025-12-31171.4%
Q32026-03-31-340.0%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q3 2026YOY CHG

Revenue

CA$0.00

N/A

Gross Profit

-CA$47.12

N/A

Gross Margin

0.00%

N/A

Market Cap

$7.53MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$2.51M

N/A

Employees

3

N/A

Net Income

-CA$507.81K

+12.0%

EBITDA

-CA$462.77K

+19.8%

Quarterly Fundamentals

Name
Q3 2026YOY CHG

Total Cash

CA$22.72K

-51.1%

Total Debt

CA$70.95K

+8.2%

Accounts Receivable

CA$69.70K

N/A

Inventory

CA$0.00

N/A

Long Term Debt

CA$70.95K

+8.2%

Short Term Debt

CA$0.00

N/A

Return on Assets

-37.70%

N/A

Return on Invested Capital

33.44%

N/A

Free Cash Flow

-CA$218.00

+99.7%

Operating Cash Flow

-CA$218.00

+99.7%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
CPIVFCaptiva Verde Wellness Corp.
$0.03+0.00%
CANNTrees Corporation
$0.03-3.77%
RAFARafarma Pharmaceuticals, Inc.
$0.03-20.00%
CNGGFCann Group Limited
$0.00+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
INTCIntel
$92.32-0.08%
NOKNokia
$9.10-0.06%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$7.42-0.04%
ONDSOndas
$7.80-0.02%

Questions About RVVTF

What is the current price of Revive Therapeutics?

Revive Therapeutics is trading at $0.02 per share.

What is the 52-week range for Revive Therapeutics?

Over the past 52 weeks, Revive Therapeutics has traded between $0.00 and $0.06.

How much debt does Revive Therapeutics have?

As of the most recent reporting period, Revive Therapeutics reported total debt of CA$50.71K.

How much cash does Revive Therapeutics have on hand?

Revive Therapeutics reported CA$16.24K in cash and cash equivalents in its most recent financial results.

What is Revive Therapeutics’s dividend yield?

Revive Therapeutics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services